Vimarsana
Biggest News Aggregation in the World

Tobin Schilke News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tobin Schilke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tobin Schilke Today - Breaking & Trending Today

Rhenman & Partners Asset Management AB Has $4.18 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Vimarsana News

Rhenman & Partners Asset Management AB Has $4.18 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

Rhenman & Partners Asset Management AB Has $4.18 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Vimarsana News

Rhenman & Partners Asset Management AB Has $4.18 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Moderate Buy" by Analysts - Vimarsana News

Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average […]

Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $11.50 - Vimarsana News

Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $11.50

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The […]

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update - Vimarsana News

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

28.02.2024 - Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2023 was $69.8 ...